University of Wisconsin Carbone Cancer Ctr
Welcome,         Profile    Billing    Logout  
 16 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Traynor, Anne
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
09/25
01/26
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
MATISSE, NCT05742607 / 2022-001903-42: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma, Innate Pharma SA
Non Small Cell Lung Cancer
06/25
09/26
NCT04146571: Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Available
N/A
US
Ensartinib, X-396, X396
Xcovery Holding Company, LLC
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
 
 
Leal, Ticiana
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
Schumacher, Kristen
NCT04146571: Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Available
N/A
US
Ensartinib, X-396, X396
Xcovery Holding Company, LLC
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
 
 

Download Options